In 47 patients with GI cancers and persistent chemotherapy-induced thrombocytopenia, avatrombopag corrected CIT and prevented recurrence in 70% vs 17% with placebo (P<.001) at a planned interim analysis; adverse events 78% vs 46%, serious 17% vs 0%.
RCTn = 47
Al-Samkari et al. Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial